Overview

ch14.18/CHO Bridging Study

Status:
Completed
Trial end date:
2012-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the safety, pharmacokinetic and activity profiles of the ch14.18 antibody produced in cells of hamster origin (ch14.18/CHO).
Phase:
Phase 1
Details
Lead Sponsor:
St. Anna Kinderkrebsforschung
Collaborators:
Charite University, Berlin, Germany
Istituto Giannina Gaslini
St. Anna Children's Hospital, Vienna
Treatments:
Antibodies
Antibodies, Monoclonal
Dinutuximab